Robert Knobler, MD of the Medical University of Vienna, Vienna, Austria talks about extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma (the particular varient being Sézary syndrome) at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Extracorporeal photopheresis was invented in 1983 and became well known worldwide in 1987 when the first study was published in the New England Journal of Medicine. Prof. Knobler's role was to review the literature and the progress that has been done in the past 30 years in the use of this therapy. The literature of over 37 published papers (review articles and retrospective studies) have been reviewed and it has been found that the efficacy of this therapy, which was shown to be significant in inducing complete remission (CR) in refactory patients as well as patients who were responding to other therapies but not optimally, has been reproduced in over 1200 patients that were treated with this technology. The complete remission (CR) rates
One of the most common forms of T-cell lymphoma is cutaneous T-cell lymphoma (CTCL). The two most common types of CTCL are mycosis fungoides and Sezary syndrome. Learn more about CTCL, treatment options and patient resources at www.lymphoma.org.
The following video will help you see the experience through the eyes of Sherry, a real CTCL patient.
Important Safety Information:
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen is not appropriate for patients who have had a reaction to psoralen compounds, patients who have had a light sensitive disease, or patients with an absence of one or both lenses of the eye.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate blood volume changes or patients with blood clotting disorders. See Important Safety Information for additional details.
For complete information on product indications, adverse events, contraindications, warnings and precautions, please click on Important Safety Information.